Welcome to our dedicated page for Cannabix Technol news (Ticker: BLOZF), a resource for investors and traders seeking the latest updates and insights on Cannabix Technol stock.
Cannabix Technologies Inc. (OTC: BLOZF) appears in its public news releases as a developer of marijuana and alcohol breath testing devices for workplaces, law enforcement and other safety-focused environments. The BLOZF news feed on Stock Titan aggregates these disclosures, giving investors and observers a single place to review the company’s reported milestones and product updates.
Company news frequently highlights progress on the Marijuana Breath Test (MBT)
Another recurring topic in Cannabix news is the BreathLogix autonomous alcohol screening platform. Announcements describe sales agreements with customers in sectors such as maritime shipping and oil and gas transportation, integration of BreathLogix with the cloud-based BreathLogix Connect portal, and features such as pre-access alcohol testing, real-time reporting and identity confirmation.
Readers of the BLOZF news page can review updates on regulatory milestones, such as FCC and Canadian emissions testing for the BCU and NHTSA Conforming Products List status for BreathLogix Workplace Series devices, as well as patent developments like the grant of a U.S. patent for contact-free breath analysis. For those tracking Cannabix’s progress in breath-based cannabis and alcohol detection technologies, this news stream offers a consolidated view of the company’s self-reported activities and partnerships over time.
Cannabix Technologies Inc. is advancing marijuana breathalyzer technology for law enforcement and workplace settings. The Company will present at the Texas Impaired Driving Forum in February 2022, showcasing innovations in their THC breath analyzer devices. The version 4.0 THCBA is undergoing testing, demonstrating improved accuracy and reduced costs. Recent developments include a partnership with Dr. Richard Yost for FAIMS technology. As Germany prepares to legalize cannabis, Cannabix is exploring opportunities in this emerging market. The Company remains focused on ensuring public safety through its innovative solutions.
Cannabix Technologies is advancing its marijuana breathalyzer devices aimed at law enforcement and workplace safety. Recent tests have shown the FAIMS technology effectively isolates THC, providing important data on marijuana impairment. Engineers are working on making the device more portable and battery-powered, ensuring ease of use in the field. The technology aims to enable rapid, on-site testing of breath samples for THC detection, which could significantly enhance public safety by identifying recent cannabis use. The company is in advanced prototype and pre-clinical testing stages.
Cannabix Technologies is advancing its Marijuana Breathalyzer devices, notably the THC Breath Analyzer (THCBA), designed for law enforcement and workplace drug testing. The company is increasing beta testing at a high-volume clinic in the Northwestern US and has shipped units to a biomedical clinic in Ontario. The THCBA tests for recent THC use in under five minutes and is undergoing enhancements for manufacturability and performance. Preliminary discussions with North American manufacturers have commenced, with version 4.0 targeted for production by Q4 2021.
Cannabix Technologies has received a patent from the United States Patent and Trademark Office for its innovative Marijuana Breathalyzer device, designed for law enforcement and workplace applications. The patent, numbered 17/019728, enhances the company's FAIMS technology for detecting THC in breath samples. Cannabix continues to expand its intellectual property portfolio with recent patents from both the USPTO and the Canadian Intellectual Property Office. The breathalyzer aims to provide a reliable method for identifying recent marijuana use and potential impairment.
Cannabix Technologies has received patent No. 2887841 for its Marijuana Breathalyzer device, enhancing its intellectual property in cannabis detection technology. The device, aimed at law enforcement and employers, detects THC to ensure public safety. Following this, Cannabix delivered its THC Breath Analyzer for beta testing at a leading clinic in the U.S. The evolving legal landscape in states like Oregon and New Jersey presents opportunities for improved drug testing solutions. However, the company faces risks including market conditions and regulatory approval.
Cannabix Technologies is advancing its Marijuana Breathalyzer devices aimed at enhancing public safety for law enforcement and workplaces. The company will ship its THC Breath Analyzer to a Northwestern U.S. clinic for beta testing, building on earlier tests in California. Feedback on the device has been positive, noting its ease of use and quick testing capability. Cannabix is also expanding its facility in Burnaby, BC, to boost production and staffing. However, the company faces risks regarding product development and market conditions, with no current commercial sales.
Cannabix Technologies has received a notice of allowance from the USPTO for its patent application No. 17/019728. This patent focuses on FAIMS technology for marijuana breathalyzers aimed at law enforcement and workplaces. The device detects THC in breath with advanced ion mobility techniques. Additionally, Cannabix plans to beta test its THC Breath Analyzer (THCBA) at a clinic in the Northwestern U.S. in May, enhancing user experience and machine learning capabilities. The company continues to expand its intellectual property portfolio, receiving multiple allowances and grants in recent months.
Cannabix Technologies Inc. has received a notice of allowance from the Canadian Intellectual Property Office for its cannabis drug detection device patent application, No. 2887841, filed on April 16, 2015. This device aims to assist law enforcement and employers in identifying THC impairment through breath samples. However, a notice of allowance does not equate to a granted patent. The company continues to develop marijuana breathalyzer technology for workplace and law enforcement use, targeting improvements in public safety.
Cannabix Technologies Inc. is advancing its THC Breath Analyzer by commencing beta testing with a private drug testing clinic in the Northwestern United States. The prototype aims to provide a non-invasive method for detecting recent marijuana use, aligning detection with impairment. Current testing methods identify THC for extended periods, complicating impairment assessments. The Clinic, experienced in drug testing technologies, will assist in enhancing the device's functionality.
Beta tests will target machine learning database development and cross-reactivity analysis.
Cannabix Technologies has developed the latest prototype of its Marijuana Breathalyzer, designed to provide law enforcement and employers a means to test for recent THC use. The new device includes enhancements such as a sterilization module and improved breath flow analysis, yielding results in under five minutes. With growing legalization in the U.S., this innovative technology aims to address the challenges of current drug testing methods that fail to accurately identify impairment. Cannabix's breathalyzer targets immediate use detection, differentiating it from traditional tests.